myelodysplastic syndromes
New Therapy for MDS-Related Anemia More Effective Than Standard Epoetin Alfa
In a phase 3 trial, Reblozyl was more effective than epoetin alfa for achieving independence from red blood cell ...
JANUARY 17, 2024
FDA Approves Tibsovo for Myelodysplastic Syndromes
The FDA approved ivosidenib (Tibsovo, Servier Pharmaceuticals) for adult patients with relapsed or refractory ...
OCTOBER 26, 2023
Emerging Treatment Options for High-Risk Myelodysplastic Syndromes
During the National Comprehensive Cancer Network (NCCN) 2022 Annual Congress: Hematologic Malignancies, Uma M. ...
DECEMBER 14, 2022
New Biomarker Predicts MDS Treatment Response
Researchers have identified a new biomarker to predict treatment response for myelodysplastic syndromes (MDS), ...
MARCH 22, 2022
Load more